SBFM Sunshine Biopharma: חובות לטווח קצר של החברה

Demand for oncology care remains stable regardless of economic conditions, and therefore the price evolution of Sunshine Biopharma (SBFM) is recorded below. The current figure is 0.00. The business relies on a combination of Canadian generic sales and high-risk development of new molecules. Meanwhile, the staff is being expanded with research chemists who are incentivized by royalty bonuses and stock option programs.

This indicator measures the volume of liabilities with a maturity of up to one year, allowing for an assessment of liquidity and the risk of working capital shortages during a sharp deleveraging. By analyzing the size of short-term borrowed capital, an investor can determine the financial stability of Sunshine Biopharma (SBFM), whose oncology development expenditures remain stable regardless of macroeconomic cycles and GDP fluctuations.